Broncho-Vaxom Attenuates Lipopolysaccharide-Induced Inflammation in a Mouse Model of Acute Lung Injury
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25137135 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Min-Seok Woo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea. Hauptthemen laut MEDLINE: Acute Lung Injury, Lipopolysaccharides, Disease Models, Animal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Research Foundation of Korea, National Research Foundation of Korea.
Abstract (Originalsprache)
Acute lung injury (ALI) is a condition associated with acute respiratory failure, resulting in significant morbidity and mortality. It involves cellular changes such as disruption of the alveolar–capillary membrane, excessive neutrophil migration, and release of inflammatory mediators. Broncho-Vaxom® (BV), a lyophilized product containing cell membrane components derived from eight bacteria commonly found in the respiratory tract, is known for its potential to reduce viral and bacterial lung infections. However, the specific effect of BV on ALI has not been clearly defined. This study explored the preventive effects of BV and its underlying mechanisms in a lipopolysaccharide (LPS)-induced ALI mouse model. Oral BV (1 mg/kg) gavage was administered one hour before the intratracheal injection of LPS to evaluate its preventive effect on the ALI model. The pre-administration of BV significantly mitigates inflammatory parameters, including the production of inflammatory mediators, macrophage infiltration, and NF-κB activation in lung tissue, and the increase in inflammatory cells in bronchoalveolar lavage fluid (BALF). Moreover, BV (3 μg/mL) pretreatment reduced the expression of M1 macrophage markers, interleukins (IL-1β, IL-6), tumor necrosis factor α, and cyclooxygenase-2, which are activated by LPS, in both mouse alveolar macrophage MH-S cells and human macrophage THP-1 cells. These findings showed that BV exhibits anti-inflammatory effects by suppressing inflammatory mediators through the NF-κB pathway, suggesting its potential to attenuate bronchial and pulmonary inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea.
- Institute of Medical Sciences, Gyeongsang National University, Jinju 52727, Republic of Korea.
- Department of Convergence Medical Science, Gyeongsang National University, Jinju 52727, Republic of Korea.
- Department of Allergy and Respiratory Medicine, College of Medicine, Gyeongsang National University, Jinju 52727, Republic of Korea.
- Gyeongsang National University Hospital, Jinju 52727, Republic of Korea.
ORCID-Profile: Min-Seok Woo, Yi Yeong Jeong, Dawon Kang
Förderung
- The National Research Foundation of Korea
- National Research Foundation of Korea
Zitieren
APA
Woo, M. S., Cao, D. L., Kim, E. J., Jeong, Y. Y., & Kang, D. (2024). Broncho-Vaxom Attenuates Lipopolysaccharide-Induced Inflammation in a Mouse Model of Acute Lung Injury. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137135
Vancouver
Woo MS, Cao DL, Kim EJ, Jeong YY, Kang D. Broncho-Vaxom Attenuates Lipopolysaccharide-Induced Inflammation in a Mouse Model of Acute Lung Injury. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137135
BibTeX
@article{Woo2024,
author = {Woo, Min-Seok and Cao, Dang Long and Kim, Eun-Jin and Jeong, Yi Yeong and Kang, Dawon},
title = {Broncho-Vaxom Attenuates Lipopolysaccharide-Induced Inflammation in a Mouse Model of Acute Lung Injury},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25137135}
}
EUVIMED